Hemolytic Uremic Syndrome after Bone Marrow Transplantation: Clinical Characteristics and Outcome in Children

Iacopino, 1999, Severe thrombotic microangiopathy, Bone Marrow Transplant, 24, 47, 10.1038/sj.bmt.1701830 Uderzo, 2000, Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation, Bone Marrow Transplant, 26, 1005, 10.1038/sj.bmt.1702648 Pettitt, 1994, Thrombotic microangiopathy following bone marrow transplantation, Bone Marrow Transplant, 14, 495 Fuge, 2001, The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation, Br J Haematol., 113, 58, 10.1046/j.1365-2141.2001.02699.x Matsuda, 1999, Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children, Bone Marrow Transplant, 24, 919, 10.1038/sj.bmt.1702003 Roy, 2001, Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation, Bone Marrow Transplant, 27, 641, 10.1038/sj.bmt.1702849 Elliott, 2003, Posttransplantation thrombotic thrombocytopenic purpura, Mayo Clin Proc., 78, 421, 10.4065/78.4.421 Hongeng, 1997, Outcomes of transplantation with matched sibling and unrelated-donor bone marrow in children with leukemia, Lancet, 350, 767, 10.1016/S0140-6736(97)03098-5 Horwitz, 2001, Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta, Blood, 97, 1227, 10.1182/blood.V97.5.1227 Glucksberg, 1974, Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors, Transplantation, 18, 295, 10.1097/00007890-197410000-00001 Heslop, 1995, Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1, Lancet, 346, 805, 10.1016/S0140-6736(95)91621-0 Rooney, 1995, Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation, Lancet, 345, 9, 10.1016/S0140-6736(95)91150-2 Prentice, 1978, The analysis of failure times in the presence of competing risks, Biometrics, 34, 541, 10.2307/2530374 Gray, 1988, A class of k-sample tests for comparing the cumulative incidence of a competing risk, Ann Stat., 16, 1141, 10.1214/aos/1176350951 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc., 94, 496, 10.1080/01621459.1999.10474144 Juckett, 2001, Loss of renal function following bone marrow transplantation, Bone Marrow Transplant, 27, 451, 10.1038/sj.bmt.1702797 Poulsom, 2001, Bone marrow contributes to renal parenchymal turnover and regeneration, J Pathol., 195, 229, 10.1002/path.976 Rookmaaker, 2002, Bone marrow-derived cells contribute to endothelial repair after thrombotic microangiopathy, Blood, 99, 1095, 10.1182/blood.V99.3.1095 Furlan, 1998, von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome, N Engl J Med., 339, 1578, 10.1056/NEJM199811263392202 Tsai, 1998, Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura, N Engl J Med., 339, 1585, 10.1056/NEJM199811263392203 Van der Plas, 1999, Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura, Blood, 93, 3798, 10.1182/blood.V93.11.3798 Daly, 2002, Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver, Transfus Apheresis Sci., 27, 3, 10.1016/S1473-0502(02)00020-4 Takatsuka, 2002, Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome following allogeneic bone marrow transplantation, Bone Marrow Transplant, 29, 907, 10.1038/sj.bmt.1703565 Sarkodee-Adoo, 2003, Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A, Transfusion, 43, 78, 10.1046/j.1537-2995.2003.00282.x Ljungman, 2003, Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation, Blood, 102, 4255, 10.1182/blood-2002-10-3263 Lin, 2002, Risk factors for cytomegalovirus reactivation after CD+ T-cell-depleted allogeneic bone marrow transplantation, Transplantation, 74, 49, 10.1097/00007890-200207150-00009 Broers, 2000, Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation, Blood, 95, 2240, 10.1182/blood.V95.7.2240 Kroger, 2001, Br J Haematol., 113, 1060, 10.1046/j.1365-2141.2001.02849.x Meijer, 2002, Influence of cytomegalovirus seropositivity on outcome after T-cell-depleted bone marrow transplantation, Clin Infect Dis., 35, 703, 10.1086/342332 Alessandrino, 2000, Prompt response to high-dose intravenous immunoglobulins given as first-line therapy in post-transplant thrombotic thrombocytopenic purpura, Bone Marrow Transplant, 25, 1217, 10.1038/sj.bmt.1702441 Takatsuka, 2003, Endothelial damage caused by cytomegalovirus and human herpesvirus-6, Bone Marrow Transplant, 31, 475, 10.1038/sj.bmt.1703879 Jeejeebhoy, 1998, Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient, Transplantation, 65, 1645, 10.1097/00007890-199806270-00018 Waiser, 1999, De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection, Am J Kidney Dis., 34, 556, 10.1016/S0272-6386(99)70085-5 Fassas, 2001, Fatal disseminated adenoviral infection associated with thrombotic thrombocytopenic purpura after allogeneic bone marrow transplantation, Leuk Lymphoma, 42, 801, 10.3109/10428190109099343 Kalwak, 2003, A prospective analysis of immune recovery in children following allogeneic transplantation of T-cell-depleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors, Transplant Proc., 35, 1551, 10.1016/S0041-1345(03)00449-4 Bahlman, 2004, Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure, Circulation, 110, 1006, 10.1161/01.CIR.0000139335.04152.F3 Vesey, 2004, Erythropoietin protects against ischaemic acute renal injury, Nephrol Dial Transplant., 19, 348, 10.1093/ndt/gfg547 Vaziri, 1994, Erythropoietin enhances recovery from cisplatin-induced acute renal failure, Am J Physiol., 266, F360 Mori, 2002, Successful treatment of bone marrow transplant-associated thrombotic microangiopathy with antithrombin-III, Am J Med., 112, 81, 10.1016/S0002-9343(01)00947-0